$IZEA

IZEA (IZEA) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Wednesday, November 12, 2025 at 5:00 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Original reporting
Motley Fool · Motley Fool Transcribing, https://www.facebook.com/themotleyfool/
Published Nov 13, 2025, 5:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IZEA (IZEA) Q3 2025 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IZEABullishMed
01

Why it matters

The report suggests potential short-term gains for IZEA and related stocks, but broader market conditions could influence outcomes.

02

Market read

The earnings call has moderate to high relevance for investors in digital marketing and media sectors, with specific focus on IZEA.

03

What to watch

Market volatility, macroeconomic factors, and sector-specific risks could offset positive signals.

Timing: Immediate; reactions expected within days to weeks.

Background

The earnings call for IZEA indicates a cautiously optimistic outlook amid broader market uncertainties.

Company-level read

Ticker impact

$IZEABullishHigh confidence
Context

High relevance; directly discussed in the earnings call.

Expected impact

Moderate upward movement expected.

Evidence & confidence

Direct relevance and positive sentiment support a likely short-term increase.

Market effects

Potential positive impact on the digital marketing and media sectors.

Limited regional effects; primarily US-based companies.

Moderate; reflects broader trends in technology and media sectors.

Counterpoint

The positive sentiment may be overestimated; actual earnings results could be disappointing, leading to declines.

Key entities

  • IZEA

    A digital marketing and media company providing influencer marketing services.

  • Motley Fool

    Source of the earnings call transcript and analysis.

Related articles

$IZEAMedAI 8/10

IZEA (IZEA) Q2 2026 Earnings Call Transcript

IZEA reported Q2 2026 revenue of $5.8M, down 36% YoY, and a net loss of $0.7M, as it shifts to larger enterprise accounts. Managed services bookings fell 19% YoY, while SaaS revenue declined 32%. The company has $46.6M in cash and no long-term debt. Management highlighted new enterprise wins and an active M&A pipeline, but noted macroeconomic uncertainty.

$IZEAMed

IZEA Worldwide, Inc. (IZEA): Results of Operations and Financial Condition

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( August 11, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

$HALHighAI 8/10

Halliburton (HAL) Wins Integrated Cyprus Contract. Can Broader Services Improve Returns?

Halliburton (HAL) secured a multi-year contract from Eni (E) for the Cronos ultra-deepwater project in Cyprus, covering integrated drilling and well services. The deal aims to boost revenue per well and improve operational efficiency, though profitability depends on pricing and delivery costs. HAL's Q2 Europe/Africa revenue rose 19% sequentially, partly driven by regional activity.

$NKEMed

Baird Pulls the Plug on Its Sportswear Recovery Thesis, Downgrading NIKE and Dick’s All at Once

Baird downgraded NIKE (NKE), Dick's (DKS), adidas, Rocky Brands, and VF Corp to Neutral, citing consumer spending concerns due to oil prices and interest rates. NIKE and DKS are interconnected, with NIKE products making up 31% of DKS's merchandise. DKS shares fell 30% in August after lowering full-year expectations. Hedge fund holdings in DKS increased, while NIKE saw a decline. Baird's report suggests potential structural demand weakness in the footwear segment.

$JAZZHighAI 8/10

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.